VP, Chief Product Security Officer, Illumina
Oleg Yusim
Cybersecurity expectations for medical devices just shifted again. On June 27, 2025, the FDA issued its updated Cybersecurity in Medical Devices guidance, expanding requirements for “cyber devices,” clarifying FDORA §524B obligations, and reinforcing expectations around SBOMs, vulnerability disclosure, and update planning.
If you’ve already been working to meet the FDA’s 2023 requirements, you may be asking: What’s different this time? Where has the FDA provided more clarity? And how can you demonstrate “reasonable assurance of cybersecurity” in a world where software-driven devices now operate as part of larger digital ecosystems that include mobile apps, cloud services, and connected care platforms?
Orthogonal and a panel of experts discussed what’s new in the 2025 guidance, compare it to the 2023 version, and provide practical insights you can apply directly to your regulatory and engineering strategies.
VP, Chief Product Security Officer, Illumina
Oleg Yusim
Founder, Blue Goat Cyber
Christian Espinosa
VP of Regulatory & Quality, Orthogonal
Megan Graham
Founder & CEO, Orthogonal
Bernhard Kappe
Related Posts
Talk
Agile & Iterative Methodologies (Fast Feedback Loops)
Talk
The Value of Digital Ecosystems and How You Build Them
Talk
Lessons Learned from 2025, Plans for 2026 for Digital
Talk
SaMD Development and the Use of AI Tooling